Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

Sustainability

Hovione is committed to doing its part for a better world.

Page
Read more

Hovione Policies

Hovione is dedicated to serving the Pharma Industry by providing services and products that save human lives and improve quality of life. Our team is fully committed to our Quality, HSEEn, HR and Innovation & Entrepreneurship policies.

Page
Read more

Development by Design

Development by Design is Hovione’s proven spray-dried dispersion scale-up and tech-transfer methodology.

Page
Read more